Literature DB >> 31843903

Mechanism for antigenic peptide selection by endoplasmic reticulum aminopeptidase 1.

Petros Giastas1, Anastasia Mpakali1,2, Athanasios Papakyriakou2, Aggelos Lelis3, Paraskevi Kokkala3, Margarete Neu4, Paul Rowland4, John Liddle4, Dimitris Georgiadis3, Efstratios Stratikos5.   

Abstract

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that optimizes the peptide cargo of major histocompatibility class I (MHC-I) molecules and regulates adaptive immunity. It has unusual substrate selectivity for length and sequence, resulting in poorly understood effects on the cellular immunopeptidome. To understand substrate selection by ERAP1, we solved 2 crystal structures of the enzyme with bound transition-state pseudopeptide analogs at 1.68 Å and 1.72 Å. Both peptides have their N terminus bound at the active site and extend away along a large internal cavity, interacting with shallow pockets that can influence selectivity. The longer peptide is disordered through the central region of the cavity and has its C terminus bound in an allosteric pocket of domain IV that features a carboxypeptidase-like structural motif. These structures, along with enzymatic and computational analyses, explain how ERAP1 can select peptides based on length while retaining the broad sequence-specificity necessary for its biological function.

Entities:  

Keywords:  X-ray crystallography; enzyme; immune system; mechanism; peptide

Year:  2019        PMID: 31843903      PMCID: PMC6936583          DOI: 10.1073/pnas.1912070116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance.

Authors:  Ian A York; Michael A Brehm; Sophia Zendzian; Charles F Towne; Kenneth L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

2.  Modulating antigen processing for cancer immunotherapy.

Authors:  Efstratios Stratikos
Journal:  Oncoimmunology       Date:  2014-01-03       Impact factor: 8.110

3.  Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides.

Authors:  Efthalia Zervoudi; Athanasios Papakyriakou; Dimitra Georgiadou; Irini Evnouchidou; Anna Gajda; Marcin Poreba; Guy S Salvesen; Marcin Drag; Akira Hattori; Luc Swevers; Dionisios Vourloumis; Efstratios Stratikos
Journal:  Biochem J       Date:  2011-04-15       Impact factor: 3.857

4.  Structural Basis for Antigenic Peptide Recognition and Processing by Endoplasmic Reticulum (ER) Aminopeptidase 2.

Authors:  Anastasia Mpakali; Petros Giastas; Nikolas Mathioudakis; Irene M Mavridis; Emmanuel Saridakis; Efstratios Stratikos
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

5.  Crystal Structure of Insulin-Regulated Aminopeptidase with Bound Substrate Analogue Provides Insight on Antigenic Epitope Precursor Recognition and Processing.

Authors:  Anastasia Mpakali; Emmanuel Saridakis; Karl Harlos; Yuguang Zhao; Athanasios Papakyriakou; Paraskevi Kokkala; Dimitris Georgiadis; Efstratios Stratikos
Journal:  J Immunol       Date:  2015-08-10       Impact factor: 5.422

Review 6.  Present Yourself! By MHC Class I and MHC Class II Molecules.

Authors:  Kenneth L Rock; Eric Reits; Jacques Neefjes
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

7.  Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1.

Authors:  Tina T Nguyen; Shih-Chung Chang; Irini Evnouchidou; Ian A York; Christos Zikos; Kenneth L Rock; Alfred L Goldberg; Efstratios Stratikos; Lawrence J Stern
Journal:  Nat Struct Mol Biol       Date:  2011-04-10       Impact factor: 15.369

8.  Structural insights into the molecular ruler mechanism of the endoplasmic reticulum aminopeptidase ERAP1.

Authors:  Amit Gandhi; Damodharan Lakshminarasimhan; Yixin Sun; Hwai-Chen Guo
Journal:  Sci Rep       Date:  2011-12-13       Impact factor: 4.379

9.  High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue Inhibitor.

Authors:  Petros Giastas; Margarete Neu; Paul Rowland; Efstratios Stratikos
Journal:  ACS Med Chem Lett       Date:  2019-02-13       Impact factor: 4.345

10.  Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming.

Authors:  Grazyna Kochan; Tobias Krojer; David Harvey; Roman Fischer; Liye Chen; Melanie Vollmar; Frank von Delft; Kathryn L Kavanagh; Matthew A Brown; Paul Bowness; Paul Wordsworth; Benedikt M Kessler; Udo Oppermann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-20       Impact factor: 11.205

View more
  15 in total

1.  ERAP1 Controls the Autoimmune Response against Melanocytes in Psoriasis by Generating the Melanocyte Autoantigen and Regulating Its Amount for HLA-C*06:02 Presentation.

Authors:  Akiko Arakawa; Emma Reeves; Sigrid Vollmer; Yukiyasu Arakawa; Mengwen He; Adrian Galinski; Julia Stöhr; Klaus Dornmair; Edward James; Jörg C Prinz
Journal:  J Immunol       Date:  2021-09-27       Impact factor: 5.422

2.  A systematic re-examination of processing of MHCI-bound antigenic peptide precursors by endoplasmic reticulum aminopeptidase 1.

Authors:  George Mavridis; Richa Arya; Alexander Domnick; Jerome Zoidakis; Manousos Makridakis; Antonia Vlahou; Anastasia Mpakali; Angelos Lelis; Dimitris Georgiadis; Robert Tampé; Athanasios Papakyriakou; Lawrence J Stern; Efstratios Stratikos
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

Review 3.  HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole.

Authors:  Jonas J W Kuiper; Wouter J Venema
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

4.  Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases.

Authors:  George Stamatakis; Martina Samiotaki; Anastasia Mpakali; George Panayotou; Efstratios Stratikos
Journal:  J Proteome Res       Date:  2020-09-22       Impact factor: 4.466

5.  ERAP2 Increases the Abundance of a Peptide Submotif Highly Selective for the Birdshot Uveitis-Associated HLA-A29.

Authors:  Wouter J Venema; Sanne Hiddingh; Joke H de Boer; Frans H J Claas; Arend Mulder; Anneke I den Hollander; Efstratios Stratikos; Siranush Sarkizova; Lars T van der Veken; George M C Janssen; Peter A van Veelen; Jonas J W Kuiper
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

6.  Discovery of Selective Inhibitor Leads by Targeting an Allosteric Site in Insulin-Regulated Aminopeptidase.

Authors:  Ioannis Temponeras; Lykourgos Chiniadis; Athanasios Papakyriakou; Efstratios Stratikos
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18

7.  ERAP1 binds peptide C-termini of different sequences and/or lengths by a common recognition mechanism.

Authors:  Lufei Sui; Hwai-Chen Guo
Journal:  Immunobiology       Date:  2021-07-04       Impact factor: 3.152

8.  Discovery and Optimization of a Series of Benzofuran Selective ERAP1 Inhibitors: Biochemical and In Silico Studies.

Authors:  Safia Deddouche-Grass; Cyrielle Andouche; Felix Bärenz; Célia Halter; Arnaud Hohwald; Louison Lebrun; Nathalie Membré; Renaud Morales; Nicolas Muzet; Matthieu Poirot; Morgane Reynaud; Véronique Roujean; Fabienne Weber; André Zimmermann; Rama Heng; Nicolas Basse
Journal:  ACS Med Chem Lett       Date:  2021-06-04       Impact factor: 4.632

Review 9.  From Angiotensin IV to Small Peptidemimetics Inhibiting Insulin-Regulated Aminopeptidase.

Authors:  Mathias Hallberg; Mats Larhed
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

10.  Common allotypes of ER aminopeptidase 1 have substrate-dependent and highly variable enzymatic properties.

Authors:  Jonathan P Hutchinson; Ioannis Temponeras; Jonas Kuiper; Adrian Cortes; Justyna Korczynska; Semra Kitchen; Efstratios Stratikos
Journal:  J Biol Chem       Date:  2021-02-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.